{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-018465","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2023-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.541338+00:00","generated_at":"2026-06-20T06:43:44.412062+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcellx closes collaboration with Kite/Gilead for CART-ddBCMA; sells $100M of stock to Gilead","bullets":["Global collaboration to co-develop and co-commercialize CART-ddBCMA for relapsed/refractory multiple myeloma.","CART-ddBCMA is in Phase 2 pivotal trial; companies will co-commercialize in U.S., Kite outside U.S.","Arcellx sold 3,478,261 shares of common stock to Gilead for aggregate ~$100M.","Closing followed expiration of HSR waiting period; deal previously disclosed in December 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-018465","json":"https://secwatch.observer/filing/0001193125-23-018465.json","markdown":"https://secwatch.observer/filing/0001193125-23-018465.md","text":"https://secwatch.observer/filing/0001193125-23-018465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312523018465/0001193125-23-018465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312523018465/d434551d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T06:43:44.412062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}